Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation

Transplantation

Volumn 67, Issue 6, 1999, Pages 870-876

  Baan, Carla C ^a   Knoop, Christiaan J ^a   Van Gelder, Teun ^a   Holweg, Cecile T J ^a   Niesters, Hubert G M ^a   Smeets, Tom J M ^b   Van Der Ham, Frieda ^a   Zondervan, Pieter E ^a   Maat, Lex P W M ^a   Balk, Aggie H M M ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; INTERLEUKIN 15; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ALLOGRAFT; ARTICLE; CLINICAL ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0033608760     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199903270-00014     Document Type: Article

References (35)

1. Strom TB, Roy-Chaudhury P, Manfro R, et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 1996; 8: 688.
2. Gimsa U, Mitchison A. New perspectives on the Th1/Th2 paradigm. Curr Opin Organ Transplant 1997; 2: 18.
3. Baan CC, Weimar W. Intragraft cytokine gene expression: implications for clinical transplantation. Transpl Int 1998; 11: 169.
4. Wijngaard PLJ, Tuijnman WB, Gmelig Meyling FHJ, et al. Endomyocardial biopsies after heart transplantation: the presence of markers indicative of activation. Transplantation 1993; 55: 105.
5. Theze J, Alzari PM, Bertoglio J. Interleukin-2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17: 481.
6. Karnitz LM, Abraham RT. Cytokine receptor signalling mechanisms. Curr Opin Immunol 1995; 7: 320.
7. Soulillou JP, Cantarovitch D, LeMauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antilymphocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 1990; 322: 1175.
8. Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107.
9. Gelder van T, Zietse R, Mulder AH, et al. A double-blind placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 1995; 60: 248.
10. Friend PJ, Waldmann H, Cobbold S, et al. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. Transplantation 1991; 23: 1390.
11. Langrehr JM, Nüssler NC, Neuman U, et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus anti-thymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997; 63: 1772.
12. Gelder van T, Balk AHMM, Jonkman FAM, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996; 62: 51.
13. Vincenti F, Kirkman R, Light S, et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
14. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
15. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Souilillou JP. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
16. Gelder van T, Baan CC, Balk AHMM, et al. Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans. Transplantation 1998; 65: 405.
17. Kim YS, Li XC, Maslinski W, et al. The role of novel T-cell growth factors in rejection. Curr Opin Organ Transplant 1997; 2: 13.
18. Wilkinson PC, Newman I. Chemoattraction of human blood T lymphocytes by IL-15. J Exp Med 1995; 181: 1255.
19. de Saint-Vis B, Fugier-Vivier I, Massacrier C, et al. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J Immunol 1998; 160: 1666.
20. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the β-chain of the interleukin-2 receptor. Science 1994; 264: 965.
21. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL)-15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180: 1395.
22. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1997; 62: 543.
23. Baan CC, Niesters HGM, Metselaar HJ, et al. Increased IL-15 mRNA expression after liver transplantation. Clin Transplant 1998; 12: 212.
24. International Society for Heart Transplantation. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990; 9: 587.
25. Baan CC, Emmerik van NEH, Balk AHMM, et al. Cytokine mRNA expression in endomyocardial biopsies during acute rejection from human heart transplants. Clin Exp Immunol 1994; 97: 293.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
27. Thurkow EW, Van Der Heijden IM, Breedveld FC, et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J Pathol 1997; 181: 444.
28. Azzawi M, Hasleton PS, Kan SW, Hillier VF, Quigley A, Hutchinson IV. Distribution of myocardial macrophages in the normal heart. J Anat 1997; 191; 417.
29. Novitzky D. Selection and management of cardiac allograft donors. Curr Opin Organ Transplant 1998; 3: 51.
30. Bamford RN, Tagaya Y, Waldmann TA. Interleukin 15: What it does and how it is controlled. Immunologist 1997; 5(2): 52.
31. Chae DE, Nosaka Y, Strom TB, Maslinski W. Distribution of IL-15 receptor α-chain on human peripheral blood mononuclear cells and effect of immunosuppressive drugs on receptor expression. J Immunol 1996; 157: 2813.
32. Steiger J, Nickerson PW, Steurer W, Moscovitch-Lopatin M, Strom TB. IL-2 knock-out recipient mice reject islet cell allografts. J Immunol 1995; 155: 489.
33. Roy-Chaudhury P, Manfro RC, Steiger J, et al. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors? Transplant Proc 1997; 29: 183.
34. γ2a protein blocks DTH and enhances the acceptance of islet allografts [Abstract]. Transplantation 1998; 65: 257.
35. Nashan B, Niemeyer G, Koch M, Breidenbach Th, Schlitt HJ, Raab R. Phase II clinical trial with daclizumab (Zenapax) for prevention of acute rejection in liver transplanted patients. Transplantation 1998; 65: 266.